Physicians' Academy for Cardiovascular Education
Depending on individual patient characteristics, novel therapeutic approaches can reduce CV risk, particularly in patients at high CV risk. Prof. Landmesser expects that future guidelines will reflect these developments.
CME accredited course focussed on the role of PCSK9 inhibitors in the management of patients at increased CV risk. Member registration (free) is needed to enroll in this course
Systematic screening in relatives of probands with FH and elevated Lp(a) yielded more new cases than opportunistic testing in relatives of those without elevated Lp(a), but both approaches may be useful.
A paradigm shift in the treatment of hypercholesterolemia has occurred since the role of PCSK9 in the regulation of LDL-c was discovered. A review discussed novel strategies to reduce PCSK9 levels beyond therapy with monoclonal antibodies.
In an open-label extension study, consistent and sustained LDL-c reduction was seen upon changing the dose of alirocumab based on LDL-c level, allowing for an individualized approach.
A retrospective cohort study found that low adherence to long-term statin therapy was associated with a higher risk of all-cause mortality in patients with ASCVD.
This meta-analysis of RCTs on statins demonstrated reduced risk of most CVD outcomes in primary prevention populations, with increased risk of some side effects. A network meta-analysis revealed different benefit-harm profiles for specific statins.
In patients with progressive CAD, stabilizing or even regression of disease is possible, targeting a combination of risk factors. Prof. Ray and Prof. Jukema discuss the importance of LDL-c lowering to halt progression.
A meta-analysis of 28 large RCTs including more than 14.000 individuals aged >75 years showed that the use of statins resulted in significant reductions of major vascular events regardless of age.
In a total events analysis of ODYSSEY OUTCOMES, treatment with alirocumab reduced the total burden of fatal and nonfatal CV events in a post-ACS population, as compared with placebo.
Several incorrect beliefs exist about cholesterol lowering. Prof. Ray and prof. Montalescot discuss the importance of physician and patient education to improve their knowledge.
Mendelian randomization study suggests that CHD risk reduction of TG-lowering LPL variants and LDL-c lowering LDLR variants are similar per unit difference in ApoB-level.
